Novo Nordisk A/S (NYSE:NVO) Trading 1.2% Higher – Should You Buy?

Shares of Novo Nordisk A/S (NYSE:NVO) were up 1.2% during mid-day trading on Monday . The stock traded as high as $38.01 and last traded at $37.9690. Approximately 12,596,874 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 23,033,199 shares. The stock had previously closed at $37.52.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo announced a strategic partnership with OpenAI to embed advanced AI across drug discovery, manufacturing and commercial ops — a move investors see as accelerating candidate discovery and time-to-market for obesity/diabetes drugs. Novo Nordisk partners with OpenAI to speed drug development
• Positive Sentiment: Market initially reacted positively to the OpenAI tie-up — ADRs/ADRs coverage noted a stock uptick as investors priced in productivity and R&D upside from AI integration. Novo Nordisk Stock Rises. How OpenAI Can Help It Find the Next Ozempic.
• Positive Sentiment: Novo is expanding its pipeline beyond GLP‑1s — etavopivat is advancing in late‑stage trials for thalassemia (beta and alpha), which could open new revenue streams if successful. Novo Nordisk’s Etavopivat Trials Put Rare Blood Disorders In Focus
• Positive Sentiment: Ongoing share repurchase program (part of up to DKK 15bn plan) supports buybacks and cash return, a near-term shareholder support mechanism. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Company messaging and CEO commentary emphasize embedding AI into core operations (longer‑term productivity case), but benefits will materialize over quarters/years rather than immediately. Novo Nordisk Is Bringing AI Into The Core Of Its Business
• Negative Sentiment: Wall Street has reset price targets after weaker-than-expected Wegovy prescription data, signaling revenue and growth concerns in the U.S. GLP‑1 market. Wall Street Resets Novo Nordisk Price Target
• Negative Sentiment: Rising competition from Eli Lilly’s Foundayo and other entrants is eroding pricing power and market share expectations for Wegovy/Ozempic, a key near-term headwind. Does NVO Face Rising Competitive Pressure on LLY’s Foundayo Approval?
• Negative Sentiment: Some investors sold shares (e.g., Vltava Fund) citing fears of a deteriorating near‑term financial outlook; recent commentary and analyst revisions have amplified downside sentiment. Vltava Fund Sold Novo Nordisk (NVO) on Fear of Deteriorating Financial Outlook
• Negative Sentiment: Analyst/coverage pieces highlighting the stock’s recent steep decline and weak 2026 outlook add selling pressure despite long‑term pipeline potential. NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. Wolfe Research assumed coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective on the stock in a research note on Tuesday, March 3rd. Four research analysts have rated the stock with a Buy rating and twenty have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Up 3.6%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market capitalization of $175.61 billion, a price-to-earnings ratio of 11.33, a PEG ratio of 8.96 and a beta of 0.73. The firm has a fifty day moving average price of $40.39 and a 200 day moving average price of $48.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were issued a $1.2751 dividend. This represents a dividend yield of 723.0%. The ex-dividend date was Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 50.43%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. lifted its position in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors increased its stake in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares in the last quarter. Boston Partners purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at approximately $310,199,000. Price T Rowe Associates Inc. MD raised its holdings in Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its holdings in Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.